KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $59.6 million.

  • Biogen's Share-based Compensation fell 2063.91% to $59.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $290.8 million, marking a year-over-year decrease of 13.74%. This contributed to the annual value of $290.8 million for FY2025, which is 13.74% down from last year.
  • Per Biogen's latest filing, its Share-based Compensation stood at $59.6 million for Q4 2025, which was down 2063.91% from $75.3 million recorded in Q3 2025.
  • Biogen's 5-year Share-based Compensation high stood at $81.0 million for Q1 2025, and its period low was $54.1 million during Q2 2021.
  • For the 5-year period, Biogen's Share-based Compensation averaged around $66.9 million, with its median value being $68.8 million (2021).
  • As far as peak fluctuations go, Biogen's Share-based Compensation skyrocketed by 6626.87% in 2021, and later plummeted by 2063.91% in 2025.
  • Over the past 5 years, Biogen's Share-based Compensation (Quarter) stood at $58.8 million in 2021, then rose by 14.29% to $67.2 million in 2022, then dropped by 18.3% to $54.9 million in 2023, then soared by 36.79% to $75.1 million in 2024, then fell by 20.64% to $59.6 million in 2025.
  • Its last three reported values are $59.6 million in Q4 2025, $75.3 million for Q3 2025, and $74.9 million during Q2 2025.